The advent of GLP‐1 receptor agonists (GLP‐1 RAs) and the dual GIP/GLP‐1 RA tirzepatide marks a paradigm shift in the treatment of obesity and the obese phenotype of HFpEF.9 This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.